Obalon Therapeutics, Inc. (OBLN) |
| 3.05 -0.19 (-5.86%) 06-16 00:00 |
| Open: | 3.25 |
| High: | 4.8 |
| Low: | 2.948 |
| Volume: | 26,469,075 |
| Market Cap: | 5(M) |
| PE Ratio: | -2.22 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 28.75 |
| Resistance 1: | 26.83 |
| Pivot price: | 25.32 |
| Support 1: | 23.73 |
| Support 2: | 19.74 |
| 52w High: | 32.31003 |
| 52w Low: | 1.980001 |
Obalon Therapeutics, Inc. operates as a fully integrated medical device enterprise, concentrating its efforts on creating and commercializing innovative solutions for individuals battling obesity. The company's flagship offering is the Obalon Balloon System, specifically engineered to promote weight reduction in obese patients. This comprehensive system incorporates an ingestible capsule that houses an inflatable balloon connected to a microcatheter. It also includes the Obalon Navigation System console, a specialized hardware and software platform used to precisely monitor and display the balloon's location during its placement. Further components are the Obalon Touch Inflation Dispenser, a semi-automated, portable instrument for inflating the balloon once it's correctly positioned, and a single-use canister containing a gas mixture. By February 27, 2020, Obalon Therapeutics managed three company-owned treatment centers situated in California. The firm was established in 2008 and bases its operations in Carlsbad, California.
| EPS | -1.620 |
| Book Value | 16.190 |
| PEG Ratio | 7.05 |
| Gross Profit | 3.754 |
| Profit Margin (%) | -2.75 |
| Operating Margin (%) | -4.15 |
| Return on Assets (ttm) | 0.1 |
| Return on Equity (ttm) | -9.8 |
Fri, 01 Dec 2023
ReShape and Obalon Merge in All-Stock Transaction - Medical Device and Diagnostic industry
Sat, 29 Jul 2023
Jonah Shacknai Net Worth (2026) - GuruFocus
Wed, 30 Nov 2022
Dp Vii Associates Lp Net Worth (2026) - GuruFocus
Thu, 22 Aug 2019
The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrop - Benzinga
Thu, 15 Aug 2019
How to Invest in Biotech Stocks - StocksToTrade
Mon, 24 Jun 2019
Obalon readies $17m offering for retail pivot - MassDevice
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |